skip to Main Content
Treating Patients
Like Individuals®
Precision Dosing Made Easier.
About Baysient® Schedule a Demo

Who is Baysient?

Baysient creates cloud-based software to facilitate individualized dosing of anti-inflammatory MAbs to improve outcomes in patients with inflammatory diseases like IBD. Baysient’s software uses Bayesian models, routine lab results and demographic information to allow physicians to individualize dosing to a specific target trough level.

read more

Why Baysient?

QUICK, SIMPLE AND EASY-TO-USE DOSAGE CALCULATOR
EFFORTLESS SETUP SO SIMPLE YOU’LL BE LIVE IN MINUTES
SAVE TIME AND REQUIRE LESS DRUG LEVELS
TAKE OUT THE GUESSWORK, CALCULATE A PRECISE MODEL-INFORMED DOSE IN SECONDS

Introducing

An integrative, cloud-based software that facilitates individualized dosing of all marketed MAbs used to treat a wide range of inflammatory diseases.

read more

How Does It Work?

Schedule a Demo

Interested in how iDose can improve your patient outcomes?

Diane R. Mould, PhD

Chief Science Officer, Baysient LLC

Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.

Latest Blog Post

Use of Baysient iDose Found to Improve Infliximab Durability and Reduce Immunogenicity

For patients living with inflammatory bowel disease (IBD), Infliximab (IFX), a monoclonal antibody, has emerged as an efficient treatment for disease activity reduction and IBD patient life quality improvement. However, while IFX is an effective treatment for some patients, a proportion of patients lose response…

Read More
Back To Top